Regular use of over-the-counter non-steroidal inflammatory drugs (NSAIDs) such as aspirin and ibuprofen is associated with an increased risk of dying in patients diagnosed with Type 1 endometrial cancers,
In this observational study, a multi-institutional team of cancer researchers sought to understand the association of regular NSAID use and the risk of dying from endometrial cancer among a cohort of more than 4,000 patients.
They found that regular NSAID use was associated with a 66 percent increased risk of dying from endometrial cancer among women with Type 1 endometrial cancers, a typically less-aggressive form of the disease.
This danger is never mentioned in the CDC’s recommendation to use NSAIDs instead of opioids.
The association was statistically significant among patients who reported past or current NSAID use at the time of diagnosis, but it was strongest among patients who had used NSAIDs for more than 10 years in the past but had ceased use prior to diagnosis. Use of NSAIDs was not associated with mortality from typically more aggressive, Type 2 cancers.
“There is a increasing evidence that chronic inflammation is involved in endometrial cancer and progression and recent data suggests that inhibition of inflammation through NSAID use plays a role,”
Our finding was surprising because it goes against previous studies that suggest NSAIDs can be used to reduce inflammation and reduce the risk of developing or dying from certain cancers, like colorectal cancer.”
“It is important to remember that endometrial cancer patients are far more likely to die of cardiovascular disease than their cancer so women who take NSAIDs to reduce their risk of heart attack – under the guidance of their physicians – should continue doing so.
While these data are interesting, there is not yet enough data to make a public recommendation for or against taking NSAIDS to reduce the risk of cancer-related death.”
Though this was found only in the case of endometrial cancer, who knows what other damages from NSAIDs they’ll find after 100 million people in pain start taking them regularly for life.
Reference Article: Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence, Theodore M. Brasky, Ashley S. Felix, David E. Cohn, D. Scott McMeekin, David G. Mutch, William T. Creasman, Premal H. Thaker, Joan L. Walker, Richard G. Moore, Shashikant B. Lele, Saketh R. Guntupalli, Levi S. Downs, Christa I. Nagel, John F. Boggess, Michael L. Pearl, Olga B. Ioffe, Kay J. Park, Shamshad Ali and Louise A. Brinton, Journal of the National Cancer Institute, doi: 10.1093/jnci/djw251, published online December 2016.